Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Booth

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
Frontiers in Oncology|November 21, 2022
GZ17-6.02 kills prostate cancer cells <i>in vitro</i> and <i>in vivo</i>Laurence Booth, Jane L Roberts, Cameron West, et al.
Anti-Cancer Drugs|September 13, 2023
Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cellsLaurence Booth, Andrew Poklepovic, John F Hancock, et al.
Anti-Cancer Drugs|October 16, 2023
Autophagy as a therapeutic mechanism to kill drug-resistant cancer cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Frontiers in Oncology|August 6, 2019
The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by NeratinibLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Pigment Cell & Melanoma Research|September 5, 2021
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signalingPaul Dent, Laurence Booth, Andrew Poklepovic, et al.
Oncotarget|March 5, 2024
GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cellsLaurence Booth, Jane L Roberts, Cameron West, et al.
Frontiers in Oncology|October 4, 2021
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma CellsJane L Roberts, Laurence Booth, Andrew Poklepovic, et al.
Oncotarget|January 16, 2017
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]Laurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Oncology Signaling|February 12, 2019
NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Kinase inhibitors: look beyond the label on the bottlePaul Dent, Andrew Poklepovic, Laurence Booth, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
Frontiers in Oncology|November 21, 2022
GZ17-6.02 kills prostate cancer cells <i>in vitro</i> and <i>in vivo</i>Laurence Booth, Jane L Roberts, Cameron West, et al.
Anti-Cancer Drugs|September 13, 2023
Cellular responses after (neratinib plus pemetrexed) exposure in NSCLC cellsLaurence Booth, Andrew Poklepovic, John F Hancock, et al.
Anti-Cancer Drugs|October 16, 2023
Autophagy as a therapeutic mechanism to kill drug-resistant cancer cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Frontiers in Oncology|August 6, 2019
The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by NeratinibLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Pigment Cell & Melanoma Research|September 5, 2021
Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signalingPaul Dent, Laurence Booth, Andrew Poklepovic, et al.
Oncotarget|March 5, 2024
GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cellsLaurence Booth, Jane L Roberts, Cameron West, et al.
Frontiers in Oncology|October 4, 2021
Axitinib and HDAC Inhibitors Interact to Kill Sarcoma CellsJane L Roberts, Laurence Booth, Andrew Poklepovic, et al.
Oncotarget|January 16, 2017
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]Laurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Oncology Signaling|February 12, 2019
NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Kinase inhibitors: look beyond the label on the bottlePaul Dent, Andrew Poklepovic, Laurence Booth, et al.
Pageof 10